Graded exercise therapy compared to activity management for paediatric chronic fatigue syndrome/myalgic encephalomyelitis: pragmatic randomized controlled trial.
Gaunt, Daisy M, Brigden, Amberly, Harris, Shaun R S et al. · European journal of pediatrics · 2024 · DOI
Quick Summary
This study compared two types of treatment for children with ME/CFS: graded exercise therapy (gradually increasing physical activity) and activity management (focusing on managing daily activities at school, home, and socially). After 6 and 12 months, both treatments showed only small improvements, and there was no clear difference between them. In fact, children receiving exercise therapy showed a slightly higher risk of getting worse.
Why It Matters
This large, rigorously designed pragmatic trial directly addresses a major clinical question in paediatric ME/CFS: whether exercise-based interventions benefit children with this condition. The findings challenge the use of GET as first-line therapy and suggest activity management may be a safer, equally effective alternative, potentially shifting clinical practice toward more conservative approaches.
Observed Findings
Both GET and AM groups showed minimal improvement in physical function over 6-12 months, with no statistically significant between-group difference.
27% of GET participants showed deterioration compared to 17% of AM participants (weak evidence; p=0.069).
GET showed isolated evidence of anxiety reduction (HADS anxiety and Spence anxiety scales) not observed in AM.
Secondary outcomes (fatigue, depression, school attendance, pain, accelerometer-measured activity) showed similar patterns in both groups.
At conventional UK cost-effectiveness thresholds, GET had only 18-21% probability of being more cost-effective than AM.
Inferred Conclusions
GET was not more effective or cost-effective than AM for paediatric ME/CFS in this NHS setting.
Activity management may be a safer first-line approach, with equivalent or superior outcomes and lower deterioration risk.
Neither intervention produced substantial clinical improvement in the 6-12 month timeframe, suggesting both may require refinement or that ME/CFS in children requires different treatment approaches.
Remaining Questions
Why was clinical improvement so limited in both groups, and would longer treatment duration or different intervention protocols yield better outcomes?
What This Study Does Not Prove
This study does not prove that exercise is harmful in ME/CFS—only that structured graded exercise therapy was not superior to activity management in this population. It does not address whether different exercise protocols, durations, intensities, or patient subgroups might respond differently. The modest improvements in both groups also limit conclusions about optimal treatment for paediatric ME/CFS overall.
Are there subgroups of children (by age, severity, symptom phenotype) more likely to benefit from GET versus AM?
What accounts for the apparent increased deterioration risk with GET, and does this reflect disease progression, deconditioning, or post-exertional malaise?
What should optimal treatment for paediatric ME/CFS be, given neither approach produced substantial benefit in this trial?